Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II trial sought to establish the impact of DYNE-251 on mobility-related endpoints, seeing an increase over baseline at 12 months.

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...

Dyne Therapeutics reports positive long-term data for DYNE-251 in Duchenne muscular dystrophy, aiming for U.S. accelerated approval in 2026. Dyne Therapeutics announced new long-term clinical data ...

Patients with Duchenne muscular dystrophy (DMD) have seen an “unprecedented and sustained” functional improvement in a Phase I/II trial examining Dyne Therapeutics’ DYNE-251. Announced as ...

the analyst expects DYNE-251, DYN’s investigational therapeutic for Duchenne muscular dystrophy, to become the company’s first commercial product with a potential commercialization in 2026.

Furthermore, in DMD, we expect data from the ongoing DELIVER trial of DYNE-251 in late 2025 to support a potential submission for U.S. Accelerated Approval in early 2026, giving us the ...